# YGION Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ygion-biomedical

- Industry: Biotechnology
- Headquarters: Vienna, Austria
- Website: www.ygion.bio
- Total disclosed funding: $16M
- Latest round: Series A (May 21, 2024)
- Investors on record: 1

## About

Based in Vienna, Austria, and founded in 2022 by Wolfgang Fischl, Georg Casari, Alexander Seitz, Geert Mudde, and Gottfried Himmler, YGION Biomedical GmbH, a.k.a. YGION Biomedical operates as a biotechnology company that focuses on developing individualized neoantigen-based cancer vaccines. In May 2024, YGION Biomedical GmbH raised EUR 15 million in a Series A funding from the Austrian Angel Investors Association.

The company provides cancer treatment by developing targeted therapies that harness the patient’s immune system to fight tumors. approach involves a proprietary immune-modulating carrier, CARGONAUT, which delivers neoepitope peptides to antigen-presenting cells, triggering a precise and potent immune response. Using advanced tumor genomics and bioinformatics, YGION's YGNITE platform creates personalized plug-and-play cancer vaccines tailored to each patient's tumor.

The company plans to use its proceeds from May 2024 funding to further develop its YGNITE technology platform and advance the lead program YG-01 into preclinical and clinical development.

## Funding rounds

- Series A, May 21, 2024, $16M — Austrian Angel Investors Association

## Investors

- Austrian Angel Investors Association (https://capitalatlas.ai/funds/austrian-angel-investors-association) — Series A